Cellentia

Executive Summary

Cellentia is a specialized contract research organization (CRO) based in Cambridge, Massachusetts, founded in 2018. The company offers custom bioassay development, analytical services, and patient-derived 3D tumor organoid lines to support oncology and cell therapy research. Its core services include PBMC isolation, MSD and ELISA assays, mycoplasma testing, and organoid culturing. By providing these critical tools, Cellentia enables pharmaceutical and biotechnology clients to accelerate drug development and reduce attrition rates. The company's focus on patient-derived organoids positions it at the forefront of personalized medicine, offering more physiologically relevant models than traditional 2D cultures. With a lean operational model and deep expertise in immuno-oncology assays, Cellentia has carved a niche in the competitive CRO landscape. Looking ahead, Cellentia is poised for growth by expanding its service menu and forging strategic partnerships. The increasing demand for complex bioanalytical services in oncology and cell therapy, coupled with the trend toward outsourcing non-core R&D activities, provides a tailwind for the company. While still privately held and relatively small, Cellentia's specialized capabilities and location in the vibrant Cambridge biotech hub position it well to capture market share. However, competition from larger CROs and the need for continuous technological investment present challenges. Overall, Cellentia represents a focused service provider with potential for steady expansion in a growing market.

Upcoming Catalysts (preview)

• Q4 2026Launch of new organoid-based drug sensitivity testing service70% success
• Q1 2027Strategic partnership with a mid-size pharmaceutical company for cell therapy assay development50% success
• Q2 2027Expansion into new laboratory facility to increase capacity80% success